IP Library › Patent Application 17028724
Patent Application
App. No. 17/028,724

Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/028,724
Abstract

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims (2)

1 . A compound of the Formula:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 17028319 PREVIOUSLY RECORDED AT REEL: 053997 FRAME: 0501. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 28, 2022
From: SOMMADOSSI, JEAN-PIERRE; MOUSSA, ADEL
To: ATEA PHARMACEUTICALS, INC.
Reel/Frame 062003/0409 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2020
From: SOMMADOSSI, JEAN-PIERRE; MOUSSA, ADEL
To: ATEA PHARMACEUTICALS, INC.
Reel/Frame 054369/0895 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: SOMMADOSSI, JEAN-PIERRE; MOUSSA, ADEL
To: ATEA PHARMACEUTICALS, INC.
Reel/Frame 053997/0501 →